The Evaluation Characteristics of Type B Aortic Intramural Hematoma and Ten Years Treatment Outcomes

• 作者: Jinguo Zhu Hongbo Hu
• 来源期刊: 心血管病(英文)
• 学科: 数学
• 关键词: IMH-B Aortic Related Events Treatment Strategies
• 年，卷（期）: 2021,（1）
• 页码范围: 58-68
• 页数: 11页
• 分类号: O17

摘要

<strong>Background</strong><strong>:</strong><span style="font-family:;" "=""><span style="font-family:Verdana;"> Type B aortic</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">intramural hematoma (IMH-B) is recognized as a subset of aortic dissection. The evolution of uncomplicated IMH-B is very difficult to predict. How and when to deal with this disease is unclear. The present study constructed two models to explore this problem. One is the</span><b><span style="font-family:Verdana;"> </span></b><span style="font-family:Verdana;">morphology evolution model, which explored the risk factors and predictors for the IMH-B patients. Another is the predictive model confirmed the predictors and the time for invasive treatment of uncomplicated IMH-B patients.</span></span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Objective: </span></b><span style="font-family:Verdana;">To explore the evolution predictors and detect the time for invasive treatment of uncomplicated IMH-B patients.</span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:;" "=""><span style="font-family:Verdana;">The</span><b></b><span style="font-family:Verdana;">morphology evolution model demonstrated that all 81 patients were diagnosis with CTA images. The initial and follow-up data were retrospectively studied. The evolution data were collection and measurement from initial and follow-up CTA images data. The predictive model showed that predictors of progression were detected with cox regression analysis.</span></span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">All 81IMH-B patients were followed-up ranged from 1.2 to 36 months (median, 22 months). 26 patients accepted invasive treatment (24 underwent TEVAR and 2 underwent Surgery)</span><span style="font-family:Verdana;">. </span><span style="font-family:Ver